Premium
Role of the HLA ‐C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients
Author(s) -
Talamonti M.,
Galluzzo M.,
Reek J.M.,
Jong E.M.,
Lambert J.L.W.,
Malagoli P.,
Bianchi L.,
Costanzo A.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15387
Subject(s) - ustekinumab , medicine , psoriasis , cohort , psoriasis area and severity index , retrospective cohort study , plaque psoriasis , gastroenterology , immunology , adalimumab , disease
Summary Background Little is known about the role of the HLA ‐C*06 allele in the response to psoriasis treatments. Objectives To confirm the role of HLA ‐C*06 as a pharmacogenetic marker of response to ustekinumab in a new, large cohort of patients involving four European centres. Methods In this retrospective multicentre study we reviewed data of 255 patients with psoriasis genotyped for HLA ‐C*06 who started ustekinumab treatment between January 2014 and March 2015. The severity of psoriasis and response to treatment were evaluated using the Psoriasis Area and Severity Index ( PASI ) score at baseline and then at follow‐up visits on weeks 4, 12, 28, 40 and 52. The primary end point was the proportion of patients achieving ≥ 50% reduction in PASI score ( PASI 50) at week 4. A ≥ 75% reduction in PASI score ( PASI 75) and a ≥ 90% reduction in the PASI score ( PASI 90) after 12 weeks were secondary end points. Results At week 4, PASI 50 was seen in 71·7% of HLA ‐C*06 ‐positive (C*06 POS ) and 35·2% of HLA ‐C*06 ‐negative (C*06 NEG ) patients. At week 12, PASI 75 was reached by 69.1% of C*06POS patients and 40·5% of C*06NEG patients. After 52 weeks, PASI 75 was reached by 83.7% of C*06POS patients and 58.8% of C*06NEG patients. Conclusions The results from our new, large cohort of European patients treated with ustekinumab in daily clinical practice confirm the role of HLA ‐C*06 as a potential predictor of response to ustekinumab.